Bisfosfonatos y osteonecrosis maxilar: una revisión de la literatura narrativa
DOI:
https://doi.org/10.33448/rsd-v12i4.41166Palabras clave:
Bisfosfonato; Osteonecrosis; Mandíbulas; Odontología.Resumen
Los bisfosfonatos son una clase de medicamentos que se usan en el tratamiento de enfermedades que causan reabsorción ósea, incluida la osteoporosis, la enfermedad de Paget del hueso, así como enfermedades relacionadas con malignidad, como el mieloma múltiple. Uno de sus mecanismos de acción es la inhibición de la actividad de los osteoclastos. Desde 2003, estudios reportan la asociación de osteonecrosis avascular de los huesos maxilares con el uso de bisfosfonatos, siendo un ejemplo de reacción adversa. Varios signos y síntomas dan lugar a sus manifestaciones clínicas, debido a complicaciones en la terapia con bisfosfonatos, y pueden ser asintomáticos o, en algunos casos, cursar con dolor y necrosis cuando hay exposición del hueso mandibular o maxilar. Así, el objetivo de este estudio fue realizar una revisión bibliográfica acerca de la relación entre la osteonecrosis de los maxilares y el uso de bisfosfonatos. Para realizar esta revisión bibliográfica se evaluaron artículos científicos investigados en inglés y portugués sin límite de año de publicación en las siguientes bases de datos: PubMed, SciELO (Scientific Electronic Library Online, Scopus Elsevier, BVS (Virtual Health Library) y Academic Google Utilizando los descriptores: “Bifosfonatos, Osteonecrosis, Mandíbulas, Odontología”, se concluye que la osteonecrosis de los maxilares es una enfermedad que puede estar relacionada con el uso de bisfosfonatos, y que aún no existe un tratamiento estándar para esta patología, idealmente , antes de iniciar el tratamiento con bisfosfonatos, el paciente debe acudir a una cita odontológica para realizar posibles tratamientos invasivos y conseguir una buena salud bucodental.
Citas
Abu-Id, M. H. et al. (2008). “Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg, 36, 95-103.
Agrillo, A. et al. (2012). Osteonecrose da mandíbula por bisfosfonatos (BRONJ): 5 anos de experiência no tratamento de 131 casos com terapia de ozônio. Eur Rev Med Pharmacol Sci., 16, 1741-1747.
Akashi, M. et al. (2018). A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw. Journal of Oral and Maxillofacial Surgery, 22(4), 369–378.
Aldhalaan, N. A., Baqais, A. & Al-Omar, A. (2020). Osteonecrose relacionada à medicação da mandíbula: uma revisão. O Cureus. 2(12), 10.
Allegra, A. et al. (2014). Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. Journal of Cranio-Maxillo-Facial Surgery, 42(4), 279–282.
Allen, M. R. & Ruggiero, S. L. (2009). Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. Journal of Oral and Maxillofacial Surgery, 67(7), 1373–1377.
Almazrooa, S. A. & Woo, S. B. (2009) Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis of the Jaw: A Review. The Journal of the American Dental Association, 140(7), 864-875.
Baba, A. C. T. (2018). Imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol, 47(4).
Bagan, J. et al. (2013). Bisphosphonates-related osteonecrosis das mandíbulas: um estudo preliminar de interleucinas salivares. Journal of Oral Pathology Medicine, 42, 405-408.
Barni, S. et al. (2006). Bisphosphonates and metastatic bone disease. Annals of Oncology, 17(2), 91–95.
Bianchi, S. D. et al. (2007). Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 104(2), 249–258.
Brozoski, M. A. et al. (2012). Osteonecrose maxilar associada ao uso de bisfosfonatos. Revista Brasileira de Reumatologia, 52(2), 265-270.
Campisi, G. et al. (2020). Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. International Journal of Environmental Research and Public Health, 17(16), 5998.
Chiandussi, S. et al. (2006). Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento Maxillo Facial Radiology, 35(4), 236–243.
Cosman, F. et al. (2014). National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos International, 25(10), 2359-2381.
Di Fede, O. et al. (2018). O tratamento odontológico de pacientes em risco de osteonecrose da mandíbula relacionada a medicamentos: novo paradigma de prevenção primária. Biomed Research International, 2018, 2684924.
Dimopoulos, M. A. et al. (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 20(1), 117-120.
Dişel, U.et al. (2012). A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncology, 48(2), 2-3.
Dore, F.et al. (2009). Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. Journal of Nuclear Medicine, 50(1), 30–35.
Drake, M. T., Clarke, B. L. & Khosla, S. (2008). Bisfosfonatos: mecanismo de ação e papel na prática clínica. Mayo Clinic Proceedings, 83(9), 1032-1045.
Drake, M. T., Clarke, B. L. & Lewiecki, E. M. (2015). The pathophysiology and treatment of osteoporosis. Clinical Therapeutics.
Fernandes, C., Leite, R. S. & Lanças, F. M. (2005). Bisfosfonatos: síntese, análises químicas e aplicações farmacológicas. Química Nova, 28(2), 274-280.
Ferreira, J. C .D., Casado, P .L. & Barboza, E. S. P. (2007). Osteonecrose associada aos bifosfonatos na odontologia. Revista Periodontia, 17(4), 24-30.
Fleisch, H. et al. (1968). A influência de análogos de pirofosfato (difosfonatos) na precipitação e dissolução de fosfato de cálcio in vitro e in vivo. Revista de tecido calcário, 2, 10.
Fleisch, H., Russel, R.G.G. & Straumann, F. (1966). Efeito do pirofosfato na hidroxiapatita e suas implicações na homeostase do cálcio. Natureza, 212, 901–903.
Fleisch. H. & Bisaz, S. (1962). Isolation from urine of pyrophosphate, a calcification inhibitor. American Physiological Society Publications, 203, 671-675.
Fleisher, K. E., Kontio, R. & Otto, S. (2016). Antiresorptive drug-related Osteonecrosis of the jaw (ARONJ) - a guide to research. Davos Platz: AO Foundation.
Gebara, S. N. & Moubayed, H. (2009). Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates American Physiological Society Publications, 66 (17), 1541-1547.
Gegler, A. et al. (2006). Bisfosfonatos e osteonecrose maxilar: revisão de literatura e relato de dois casos. Revista Brasileira de Cancerologia, 52(1), 25-31.
George, E. L., Lin, Y. L. & Saunders, M. M. (2018). Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Reports, 8(2018), 104-109.
Giribone, J. & Catagnettop. (2013). Osteonecrosis de los maxilares inducida por bifosfonatos; lo que el odontólogo debe saber hoy: pautas y protocolos. Odontoestomato.
Gong, L. et al. (2012). Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics, 21(11), 820-827.
Green, J, Czanner, G & Reeves, G. (2010). Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ, 1(341).
Gridelli, C. (2007). The Use of Bisphosphonates in Elderly Cancer Patients. The Oncologist, 12(1), 62–71.
Guggenberger, R.et al. (2013). Bisphosphonate-induced osteonecrosis of the jaw: comparison of disease extent on contrast-enhanced MR imaging, [18F] fluoride PET/CT, and conebeam CT imaging. AJNR. American journal of neuroradiology, 34(6), 1242–1247.
Gupta, M. & Gupta, N. (2021). Bisphosphonate Related Jaw Osteonecrosis. Treasure Island. StatPearls Publishing.
Haworth, A. E. & Webb, J. (2014). Complicações esqueléticas do uso de bisfosfonatos: o que o radiologista deve saber. Jornal Britânico de Radiologia, 85(1018), 1333-1342.
Hess, L. M., Jeter, J. M., Benham-Hutchins, M. & Alberts, D. S. (2008). Factors associated with osteonecrosis of the jaw among bisphosphonate users. The American Journal of Medicine, 121, 475-483.
Ikebe, T. (2013). Fisiosiologia do BRONJ: doença osteoclástica relacionada com drogas da mandíbula. Oral Science International, 10(1), 01-08.
Izquierdo, C. M., De Oliveira, M. G. & Weber, J. B. B. (2011). Terapêutica com bisfosfonatos: implicações no paciente odontológico – revisão de literatura. RFO, 16(3), 347-352.
Khan, A. A. et al. (2015). International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal Bone Miner Research, 30(1), 03-23.
Kim, J .E., Yoo, S. & Choi, S.C. (2020). Várias questões relacionadas ao diagnóstico por imagem da osteonecrose da mandíbula relacionada a medicamentos. Imaging Science in Dentistry, 50(4), 273-279.
Kimmel, D. B. (2007). Mecanismo de ação, perfil farmacocinético e farmacodinâmico, e aplicações clínicas de bisfosfonatos contendo nitrogênio. Journal of Dental Research, 86(11), 1022-1033.
Koth, V. S. et al. (2016). Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. Dento maxillo facial radiology, 45(7), 01-12.
Krishnan, A.et al. (2009). Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. Journal of Computer Assisted Tomography, 33(2), 298–304.
Kuroshima, S.et al. (2019). Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. Gerodontology, 36(4), 313–324.
Lacerda, J. C .T., Junior, A .A. C .P., Macedo, L. M., Moreira, L .I. R. & Alves, J. F .C. S. (2017). Osteonecrose dos maxilares associada ao uso de bisfosfonatos. Revista de Cirurgia e Traumatologia Buco-Maxilo-Facial.
Lau, A. N. & Adachi, J. D. (2009). Resolution of osteonecrosis of the jaw after teriparatide[recombinant human PTH-(1-34)] therapy. Journal Rheumatolog, 36(8), 1835-1837.
Lombard, T.et al. (2016). Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem Cells International, 2016, 8768162.
Mariotti, A. (2008). Bisphosphonates and osteonecrosis of the jaws. J Dent Educ, 72(8), 919-929.
Marx, R. E. (2008). Osteonecrose dos maxilares induzida por bisfosfonatos: um desafio, uma responsabilidade e uma oportunidade. Int J Periodontia Restor Dent. 28(1), 5–6.
Marx, R. E., Cillo, J. E. & Ulloa, J. J. (2007). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using sérum CTX testing, prevention, and treatment. Journal Oral Maxillofac Surge, 65(12), 2397-2410.
Mehrotra, B. & Ruggiero, S. (2006). Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program, 515, 356-360.
Melo, A .C. (2005). Osteonecrose da mandíbula em paciente portador de mieloma múltiplo: patologia secundária ao uso do pamidronato. Revista Brasileira de Hematologia e Hemoterapia, 27(3), 221-222.
Merigo, E. et al. (2006). Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed, 77(2), 109-117.
Migliorati, C. A. et al. (2006). Managing the care of patients with bisphosphonate-associate osteonecrosis An American Academy of Oral Medicine position paper. The Journal American Dental Association, 136(12), 1658-1668.
Nicolatou-Galitis, O. et al. (2019). Osteonecrose da mandíbula relacionada a medicamentos: definição e melhores práticas para prevenção, diagnóstico e tratamento. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 127(2), 117-135.
Nicolatou-Galitis, O. (2012). Osteonecrosis of the jaw (onj) in patients who receive bone targeting agents (btas): the power of e-learning. Ecancermedicalscience. 130(3), 122.
Nicolatou-Galitis, O.et al. (2015). Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 120(6), 699–706.
Omami, G. (2021). Osteonecrose da Mandíbula Relacionada a Medicamentos. Diário de ouvido, nariz e garganta, 100(8), 366-367.
Otto, S. et al. (2015). Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? Journal of Cranio-Maxillo-Facial Surgery, 43(6), 847–854.
Pan, W. L. (2017). Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report. Clinical interventions in aging, 12, 1089-1093.
Pancholi, M. (2007). Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention and treatment. British Dental Journal, 203(1), 56–57.
Papapetrou, P. D. (2009). Eventos adversos associados a bisfosfonatos. Hormones, 96-110.
Pautke, C. et al. (2011). Bisphosphonate related osteonecrosis of the jaw--manifestation in a microvascular iliac bone flap. Oral Oncology, 47(5), 425-429.
Peer, A. & Khamaisi, M. (2015). Diabetes as a risk factor for medication-related osteonecrosis of the jaw. Journal of Dental Research, 94(2), 252–260.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Pereira, F. T., Holanda, L. A. L., Medeiros, N. M., Tavares, C. L., Silva, E. D. O. & Vida, A. K. L. (2022). Mandibular osteonecrosis and the use of bisphosphonate in an oncologic patient: case report. Research, Society and Development, 11 (13)
Regev, E., Lustmann, J. & Nashef, R. (2008). Atraumatic teeth extraction in bisphosphonate-treated patients. Journal Oral Maxillofac Surgery, 66(11), 57-61.
Reis, P. M. C. (2010). Osteonecrose dos maxilares por bisfosfonato. Journal Oral Maxillofacial Surgery.
Rodriguez-Lozano, F. J. & Oñate-Sanchez, R. E. (2016). Tratamento da osteonecrose da mandíbula relacionada a bisfosfonatos e outros agentes antirreorvotivos. Medicina Oral Patología Oral y Cirugía Bucal, 21(5), 595-600.
Rosella, D.et al. (2016). Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. Journal of International Society of Preventive & Community Dentistry, 6(2), 97–104.
Ruggiero, S. L. et al. (2009). A associação americana de cirurgiões bucomaxilofaciais posiciona papel sobre osteonecrose da mandíbula relacionada a bisfosfonatos. Revista Endodôntica Australiana, 35(3), 119-130.
Ruggiero, S. L. et al. (2014). American Association ofOral and Maxillofacial Surgeons. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. Journal of Oral and Maxillofacial Surgery, 72(10), 1938-1956.
Ruggiero, S. L. (2009). Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons, 67(5), 13–18.
Ruggiero, S .L. et al. (2009). American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. Journal Oral Maxillofacilo Surgery, 67(50, 2-12.
Ruggiero, S. L., Fantasia, J. & Carlson, E. (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 102(4), 433-441.
Russell R. G. (2006). Bisphosphonates: from bench to bedside. Annals of the New York Academy Sciences.
Sales, K. O. & Conceição, L. S. (2020). A Atuação do Cirurgião-Dentista Frente À Osteonecrose dos Maxilares Associada ao Uso de Bisfosfonatos: Uma Revisão de Literatura. Facit Business and Technology Journal, 1(14), 01-12.
Santos, P. S. S. et al. (2008). Osteonecrose maxilar em pacientes portadores de doenças neoplásicas sob uso de bisfosfonatos. Revista Brasileira de Hematologia e Hemoterapia, 30(6), 501-504.
Schiodt, M. et al. (2019). Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Diseases, 25(7), 1815–1821.
Shannon, J. et al. (2011). Bisfosfonatos e Osteonecrose da mandíbula. Journal of the American Geriatrics Society, 59, 2350-2355.
Sharma, D. (2013). Bisphosphonate-related osteonecrosis of jaw (BRONJ): critérios diagnósticos e possíveis mecanismos patogênicos de um efeito colateral anti-angiogênico inesperado. Vasc. Célula, 5, 01-08.
Singh, M. G. S. (2020). Osteonecrose induzida por bisfosfonato das mandíbulas (BIONJ). Journal Maxillofacial Oral Surgery, 19(2), 162-167.
Sousa, F. R. N. & Jardim, J. E. G. (2008). Osteonecrose associada com o uso dos bifosfonatos. Pesquisa Brasileira em Odontopediatria e Clíica. Integrada, 3(8), 375-380.
Sousa, A. et al. (2018). Protocolo de atendimento odontológico de pacientes em tratamento com bisfosfonatos. Revista Saúde.
Sousa, S. R. C. et al. (2021). Avaliação do grau de conhecimento dos Cirurgiões Dentistas sobre a utilização dos bisfosfonatos e seus efeitos adversos: Estudo descritivo. Research, Society and Development, 10(6), 01-08.
Stockmann, P. et al. (2010). Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical Oral Investigations, 14(3), 311–317.
Sturrock, A. et al. (2019). Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ, 9(3), 24376.
Troeltzsch, M. et al. (2016). Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? Journal of Cranio-Maxillo-Facial Surgery, 44(12), 1945–1951.
Vescovi, P. et al. (2008). Nd-Yag laser bioestimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surgery, 26(1), 37-46.
Viviano, M., Rossi, M. & Cocca, S. (2017). A rare case of osteonecrosis of the jaw related to imatinib. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 43(2), 120–124.
Williams, W. B. & O’ryan, F. (2015). Management of Medication-Related Osteonecrosis of the Jaw. Management of Medication-related Osteonecrosis of the Jaw, 27(4), 517–525.
Woo, S. B., Hellstein, J. & Kalmar, J. R. (2006). Systematic review: bisphosphonates and osteonecrosis of the jaw. Annals of international medicine, 144(10), 753- 761.
Zara, S. et al. (2015). Zoledronic acid at subtoxic sutica extensão do estágio osteoblástico de osteoblastos humanos primários. Clinical Oral Investigigations, 19, 601-611.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Francisca Mariane Martins Monte; Manuela Almeida Montenegro Furtado
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
